Incomplete neoadjuvant chemo(radio)therapy negatively impacts pathological response and overall survival in locally advanced esophageal cancer

European Journal of Cancer

DOI: 10.1016/j.ejca.2025.115538 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 0 stored of 5

References 6

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
2021 Journal of Clinical Oncology article Medicine Esophageal Cancer Research and Treatment Open access

822

citations
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).
2024 Journal of Clinical Oncology conference-abstract Medicine Esophageal Cancer Research and Treatment Open access

99

citations
Outcomes of Esophagogastric Cancer Surgery During Eight Years of Surgical Auditing by the Dutch Upper Gastrointestinal Cancer Audit (DUCA)
2021 Annals of Surgery article Medicine Esophageal Cancer Research and Treatment Open access

82

citations
Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands
2025 EClinicalMedicine article Medicine Esophageal Cancer Research and Treatment Open access

26

citations
SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer
2021 Journal of the National Comprehensive Cancer Network article Medicine Esophageal Cancer Research and Treatment Open access

23

citations
Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the ‘CROSS-regimen’ in daily practice
2021 Diseases of the Esophagus article Medicine Esophageal Cancer Research and Treatment Open access

7

citations

6 results